Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Zilucoplan sodium
Lacuna Pharma Pty Ltd
Generalized Myasthenia Gravis
1 trial -
Zipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient, zipalertinib., Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Taiho Pharma Netherlands B.V.
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
1 trial -
Zoladex 3,6 mg implante en jeringa precargada, Decapeptyl semestral 22,5 mg polvo y disolvente para suspensión de liberación prolongada inyectable., Eligard semestral 45 mg polvo y disolvente para solución inyectable., Bicalutamida Aristo 50 mg comprimidos recubiertos con película EFG
The George Institute
Prostate Cancer
1 trial -
Zolgensma 2 × 10^13 vector genomes/mL solution for infusion
Novartis Pharmaceuticals
Spinal Muscular Atrophy
1 trial -
Zometa 4 mg/100 ml solution for infusion, XGEVA 120 mg solution for injection in pre-filled syringe
CERO THERAPEUTICS HOLDINGS, INC.
Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy
1 trial -
Zovirax 50 mg/g crema, Lipovir 50 mg/g Gel, Placebo
Lacuna Pharma Pty Ltd
Recurrent herpes labialis (RHL)
1 trial -
[18F]-AlF-FAPI-74, GlucaGen®, HypoKit met 1 mg poeder en oplosmiddel voor oplossing voor injectie, Scopolamine butylbromide Kalceks 20 mg/ml oplossing voor injectie
Disc Medicine
Cholangiocarcinoma
1 trial -
aceneuramic acid extended-release (Ace-ER)
Ultragenyx UK Limited
Hereditary Inclusion Body Myopathy
1 trial -
acyclovir
Ultragenyx UK Limited
Herpes Simplex
2 trials -
adoptive immunotherapy
Chinese PLA General Hospital
Hepatocellular Carcinoma
1 trial -
aflibercept
Regeneron UK Limited
Retinopathy of Prematurity
1 trial -
aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Regeneron UK Limited
Ovarian Neoplasms
2 trials -
aflibercept 8 mg PFS
Regeneron UK Limited
Diabetic Macular Edema (DME)
1 trial -
alirocumab SAR236553 (REGN727)
Regeneron UK Limited
Hypercholesterolaemia
2 trials -
alirocumab SAR236553 (REGN727)
Regeneron UK Limited
Hypercholesterolemia
8 trials -
alprazolam, Placebo matching Staccato® alprazolam and without active substance
Lacuna Pharma Pty Ltd
Treatment of stereotypical prolonged seizure
1 trial -
amifampridine phosphate
CATALYST PHARMACEUTICALS, INC.
Myasthenic Syndromes, Congenital
1 trial -
ampreloxetine
Theravance Biopharma Ireland Umited
Symptomatic Neurogenic Orthostatic Hypotension
4 trials -
belapectin
GALECTIN THERAPEUTICS INC
Prevention of Esophageal Varices
1 trial -
betamethasone
Ultragenyx UK Limited
Respiratory Distress Syndrome
1 trial -
bevacizumab
Outlook Therapeutics NL B. V.
Age-related Macular Degeneration
4 trials -
bevacizumab
Outlook Therapeutics NL B. V.
Neovascular Age-related Macular Degeneration
1 trial -
bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).
Lacuna Pharma Pty Ltd
Psoriatic arthritis
1 trial -
camizestrant, Arimidex® 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G
AstraZeneca AB
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources